Страница 1 от 16 резултата
Background Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) . The disease was first identified in December 2019 in Wuhan, the capital of China's Hubei province, and has since spread globally, resulting in the ongoing
Research Background and Rationale At the end of December 2019, pneumonia of unknown origin was detected in the hospitals of Wuhan city, China, and reported to the WHO country office for the first time [1-3]. After a few days, the Chinese government has confirmed the human-to-human transmission of
Between 30 and 50% of patients who contract COVID 19 will be asymptomatic or oligosymptomatic. This fact will not give rise to the consult, and will directly affect a notorious sub-registration of the cases.
The second, even more disturbing, premise is that these patients are as contagious as the
The present study is a randomized double-blind placebo controlled repeated measures design, with sampling of the cohorts on five separate occasions.
Group 1: Intervention Group (n = 24) Healthy, overweight or obese physically inactive males, supplement, n = 12 Healthy, overweight or obese physically
The study will be conducted on total group of 100 participants, from which 75 will be the patients with PAH (pulmonary arterial hypertension), HF-REF (heart failure with reduced ejection fraction) or IHD (ischemic heart disease).
In all participants medical anamnesis, physical examination,
The present study is a randomized double-blind placebo controlled repeated measures design, with sampling of the cohorts on multiple occasions. Upon obtaining informed consent participants will be randomized into one of six groups:
Healthy younger males - n=20; Healthy older males - placebo n=10,
Prior to surgery, all patients will undergo pre-anesthetic checkup including detailed history, physical, systemic examination, height and weight of the patient. All patients will be investigated for exclusion of any of the above mentioned contraindications. Routine preoperative laboratory
Prospective participants will be recruited from the Integrative Neurophysiology Laboratory's (INPL) participant database, the clinical practice of Dr. William Shaffer, Banner Health, Greeley Colorado, through advertisements in the Colorado and Wyoming Chapter of the National MS Society newsletters,
A. Patient Enrollment:
UCSD will enroll subjects with symptomatic AF undergoing clinically-indicated ablation at the Sulpizio Cardiovascular Center.
B. Research Study Data UCSD will record patient demographics (e.g. age, gender, echocardiographic information), AF history (AF duration, previous and
OUTLINE: This is a multi-center study.
INVESTIGATIONAL TREATMENT:
Regorafenib will be administered 160 mg orally once daily for the first 21 days of each 28-day cycle. Subjects that randomize to receive ginseng will take 1,000 mg orally twice daily every day for 4 weeks (2 cycles). Subjects that
Activation of the blood coagulation system is a common manifestation in cancer associated with premature death from venous thromboembolism (VTE).(1-5) Ambulatory cancer patients undergoing chemotherapy for lymphoma or cancers such as lung, ovarian, stomach, bladder, and pancreas confer a 12.6%
What will be done in this protocol? Specific to Aim 1: To investigate the correlation between changes in RBF after exposure to iodinated contrast agent, measured by CEU, on occurrence of acute kidney injury (AKI) in a population of subjects at risk for CN.
Procedures: Subjects with an estimated
A large proportion of the population has substantial left ventricular dysfunction (LVD) and do not have symptoms (Stage B heart failure). For many of these patients, if identified and treated appropriately, it is possible to prevent the subsequent development of heart failure (HF). Although the
Peripheral vascular occlusive disease is a progressive and often debilitating form of atherosclerosis affecting the vessels of the upper and lower extremities. Patients typically present with complaints of pain in the involved extremity (claudication), others present with numbness, heaviness, or
Subjects and Methods:
We propose to carry out a prospective, randomized sham placebo-controlled parallel study on 140 consecutive patients newly diagnosed with OSA, as defined by overnight sleep study showing apnea hypopnea index (AHI) >10 per hour of sleep plus excessive daytime sleepiness or two